Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CVM vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)
ENTX Overall Winner
6-Pillar Tally: CVM 2 – 3 ENTX (1 Tie)
Matrix Metrics: CVM 3 – 5 ENTX
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. CVM 43.5/100 HOLD) and 1.07β · 45% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CVM vs ENTX
CVM
Cel-Sci Corporation
$1.91
+14.76% 1D
Market Cap
$22.5M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.45β · 139% Vol
Unified Composite Score
43.5
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.01
-0.33% 1D
Market Cap
$541.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.07β · 45% Vol
Unified Composite Score
53.5
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 ENTX)
1. Valuation Multiples
CVM
Forward P/E
23.0x
N/M
Trailing P/E
23.0x
N/M
PEG Ratio
1.12x
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
CVM
Revenue Growth (YoY)
-62.7%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$28,558
N/A
Market Cap
$22.5M
$541.6M
3. Profitability & Quality
ENTX
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-252.5%
-20.3%
4. Balance Sheet & Cash Flow
ENTX
Cash Generation (TTM)
-$17M
-$16M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$6.6M Net Debt (1.24x D/E)
$265M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
N/A (N/A)
113.8% (32nd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CVM (3) vs ENTX (5)| Institutional Metric | CVM | ENTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $22.5M | $541.6M | ENTX | |
| Trailing P/E Ratio | 23.0x | N/M | CVM | |
| Forward P/E Ratio | 23.0x | N/M | CVM | |
| Revenue Growth (YoY) | -62.7% | -100.0% | CVM | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -252.5% | -20.3% | ENTX | |
| 52-Week Range Position | 15% ($1–$8) | 64% ($1–$4) | ENTX | |
| Beta / 30D Volatility | 0.45β · 139% Vol | 1.07β · 45% Vol | ENTX | |
| Unified Institutional Score | 43.5 / 100 (HOLD) | 53.5 / 100 (HOLD) | ENTX | |
| Trailing 12M Revenue (USD) | $28,558 | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.12x PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($6.6M Net Debt (1.24x D/E)) | -$16M ($265M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CVM +13.07 pp
3M Horizon
CVM +19.38 pp
6M Horizon
ENTX +117.2 pp
1Y Horizon
ENTX +82.29 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | ENTX Revenue | CVM Op. Margin | ENTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -6772.3% | N/A | CVM |
| FY2013 | $0M | N/A | -12450.1% | N/A | CVM |
| FY2014 | $0M | N/A | -9721.4% | N/A | CVM |
| FY2020 | N/A | $0M | N/A | -3059.7% | ENTX |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | N/A | $0M | N/A | -9714.2% | ENTX |
| FY2024 | N/A | $0M | N/A | -5295.6% | ENTX |
| FY2025 | N/A | $0M | N/A | -27450.0% | ENTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTX
CONSOLIDATION
Current IV
113.8%
IV Percentile
32nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CVM vs ENTX Key Questions & Quantitative Answers
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. CVM 43.5/100 HOLD) and 1.07β · 45% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), CVM cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus ENTX (-20.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTX vs CVM · Reverse Pair
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
ENTX vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking